Skandinaviska Enskilda Banken (SEB)’s AbCellera Biologics ABCL Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-340,267	Closed	-$1.16M	–	165
2025 Q4	$1.16M	Hold	340,267	–	–	﹤0.01%	616
2025 Q3	$1.71M	Hold	340,267	–	–	0.01%	587
2025 Q2	$1.17M	Hold	340,267	–	–	0.01%	636
2025 Q1	$759K	Hold	340,267	–	–	﹤0.01%	665
2024 Q4	$960K	Hold	340,267	–	–	﹤0.01%	660
2024 Q3	$885K	Buy	340,267 +31,700	+10%	+$87.8K	﹤0.01%	682
2024 Q2	$913K	Buy	308,567 +158,000	+105%	+$598K	﹤0.01%	648
2024 Q1	$682K	Buy	150,567 +59,200	+65%	+$302K	﹤0.01%	688
2023 Q4	$522K	Buy	91,367 +7,500	+9%	+$34.8K	﹤0.01%	775
2023 Q3	$386K	Buy	83,867 +3,000	+4%	+$18.3K	﹤0.01%	787
2023 Q2	$522K	Buy	+80,867	New	+$552K	﹤0.01%	785
2021 Q2	–	Sell	-65,000	Closed	-$2.23M	–	1042
2021 Q1	$2.23M	Buy	+65,000	New	+$2.59M	0.01%	625

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s ABCL Position: Q1 2026 in Review

Skandinaviska Enskilda Banken (SEB) sold out of AbCellera Biologics (ABCL) in Q1 2026, closing a stake of 340,267 shares — an estimated $1.16M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in ABCL in Q1 2021 and held it in 12 quarters. The position peaked at $2.23M in Q1 2021. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Skandinaviska Enskilda Banken (SEB) reported no remaining AbCellera Biologics position as of Q1 2026 after selling out during the quarter.
Skandinaviska Enskilda Banken (SEB) sold 340,267 AbCellera Biologics shares in Q1 2026, an estimated $1.16M.
Skandinaviska Enskilda Banken (SEB) first reported a position in AbCellera Biologics in Q1 2021 and held it in 12 quarters.
Skandinaviska Enskilda Banken (SEB)'s AbCellera Biologics position peaked at $2.23M in Q1 2021.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.